MADCAM1 and inflammatory bowel disease: As previously discussed, although natalizumab was associated with the development of PML, extensive evidence suggests that selectively targeting β7‐containing integrins or MAdCAM‐1 offers effective treatment of IBD with a favorable safety profile to date.